Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13755066 | 0.91 | MEN1 (0.43) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL4018595 | 0.90 | MEN1 (0.50) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL15624149 | 0.86 | MEN1 (0.40) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL24565358 | 0.82 | MEN1 (0.38) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL3251799 | 0.82 | CYP4F2 (0.53) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL6067617 | 0.82 | MMP8 (0.42) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL31437002 | 0.82 | MEN1 (0.42) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL15074624 | 0.82 | MEN1 (0.42) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL22323579 | 0.81 | MEN1 (0.37) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL16237400 | 0.81 | MEN1 (0.37) | MEN1KMT2AALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007786-A1 | COMPOUNDS FOR COATING OF NANOSTRUCTURES | SPAGO NANOMEDICAL AB (SE) | 2026-01-08 | — | — | US | disclosed |
| EP-4490218-A1 | COMPOUNDS FOR COATING OF NANOSTRUCTURES | Spago Nanomedical AB (SE) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023172185-A1 | COMPOUNDS FOR COATING OF NANOSTRUCTURES | SPAGO NANOMEDICAL AB (SE) | 2023-09-14 | — | — | WO | disclosed |
| EP-4242250-A1 | COMPOUNDS FOR COATING OF NANOSTRUCTURES | Spago Nanomedical AB (SE) | 2023-09-13 | — | — | EP | disclosed |
| EP-2885310-B1 | NOVEL METAL COMPLEXES, ESPECIALLY THE RUTHENIUM COMPLEXES, AND USE THEREOF | APEIRON SYNTHESIS SA (PL) | 2016-12-14 | — | — | EP | disclosed |
| US-9221042-B2 | Metal complexes, especially the ruthenium complexes, and use thereof | APEIRON SYNTHESIS S.A. (PL) | 2015-12-29 | — | — | US | disclosed |
| US-20150217283-A1 | NOVEL METAL COMPLEXES, ESPECIALLY THE RUTHENIUM COMPLEXES, AND USE THEREOF | APEIRON SYNTHESIS S.A. (PL) | 2015-08-06 | — | — | US | disclosed |
| EP-2885310-A1 | NOVEL METAL COMPLEXES, ESPECIALLY THE RUTHENIUM COMPLEXES, AND USE THEREOF | Apeiron Synthesis S.A. (PL) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014027040-A1 | NOVEL METAL COMPLEXES, ESPECIALLY THE RUTHENIUM COMPLEXES, AND USE THEREOF | UNIWERSYTET WARSZAWSKI (PL) | 2014-02-20 | — | — | WO | disclosed |
| WO-2001072421-A1 | POLYMER SUPPORTED CATALYSTS FOR OLEFIN METATHESIS | GLAXO GROUP LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150217283-A1 | NOVEL METAL COMPLEXES, ESPECIALLY THE RUTHENIUM COMPLEXES, AND USE THEREOF | ABCB7, AP1M1, NDUFS5 | MEN1 536/4885KMT2A 4512/4885ALDH1A1 796/4885 |
| US-20260007786-A1 | COMPOUNDS FOR COATING OF NANOSTRUCTURES | SCO2, PYM1, SSB | MEN1 299/4885KMT2A 1233/4885ALDH1A1 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.